Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  The Lancet

• Publication date

  2016-01-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0140-6736(15)00459-6PMID 26474810
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized Trial of Complete Versus Lesion-Only Revascularization in Patients Undergoing Primary Percutaneous Coronary Intervention for STEMI and Multivessel Disease

  2015cited by this paper
• Effects of Ranolazine in Patients With Chronic Angina in Patients With and Without Percutaneous Coronary Intervention for Acute Coronary Syndrome: Observations From the MERLIN‐TIMI 36 Trial

  2015cited by this paper
• Prognostic value of "routine" cardiac stress imaging 5 years after percutaneous coronary intervention: the prospective long-term observational BASKET (Basel Stent Kosteneffektivitäts Trial) LATE IMAGING study.

  2014cited by this paper
• Fractional flow reserve-guided PCI for stable coronary artery disease.

  2014cited by this paper
• Prognostic value of routine cardiac stress imaging 5 years after percutaneous coronary intervention

  2013cited by this paper
• Quantification of Incomplete Revascularization and its Association With Five-Year Mortality in the Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery (SYNTAX) Trial Validation of the Residual SYNTAX Score

  2013cited by this paper
• Use of ranolazine in patients with incomplete revascularization after percutaneous coronary intervention: design and rationale of the Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (RIVER-PCI) trial.

  2013cited by this paper
• Randomized trial of preventive angioplasty in myocardial infarction.

  2013cited by this paper
• Complete versus incomplete revascularization with coronary artery bypass graft or percutaneous intervention in stable coronary artery disease.

  2012cited by this paper
• Residual plaque burden in patients with acute coronary syndromes after successful percutaneous coronary intervention.

  2012cited by this paper
• Effect of Complete Revascularization on 10-Year Survival of Patients With Stable Multivessel Coronary Artery Disease: MASS II Trial

  2012cited by this paper
• Incidence, predictors and outcomes of incomplete revascularization after percutaneous coronary intervention and coronary artery bypass grafting: a subgroup analysis of 3-year SYNTAX data.

  2012cited by this paper
• Impact of the Presence and Extent of Incomplete Angiographic Revascularization After Percutaneous Coronary Intervention in Acute Coronary Syndromes: The Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) Trial

  2012cited by this paper
• Quantification and impact of untreated coronary artery disease after percutaneous coronary intervention: the residual SYNTAX (Synergy Between PCI with Taxus and Cardiac Surgery) score.

  2012cited by this paper
• The ability to achieve complete revascularization is associated with improved in‐hospital survival in cardiogenic shock due to myocardial infarction: Manitoba cardiogenic shock registry investigators

  2011cited by this paper
• Impact of Incomplete Revascularization on Long-Term Mortality After Coronary Stenting

  2011cited by this paper
• A prospective natural-history study of coronary atherosclerosis.

  2011cited by this paper
• Quantitative Results of Baseline Angiography and Percutaneous Coronary Intervention in the COURAGE Trial

  2009cited by this paper
• Fractional flow reserve versus angiography for guiding percutaneous coronary intervention.

  2009cited by this paper
• On looking at subgroups.

  2009cited by this paper
• Incomplete revascularization in the era of drug-eluting stents: impact on adverse outcomes.

  2009cited by this paper
• Heart Disease and Stroke Statistics—2015 Update: A Report From the American Heart Association

  2009cited by this paper
• Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial.

  2007cited by this paper
• Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial.

  2006cited by this paper
• Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine

  2006cited by this paper
• Impact of Completeness of Percutaneous Coronary Intervention Revascularization on Long-Term Outcomes in the Stent Era

  2006cited by this paper
• Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts.

  2006cited by this paper
• Percutaneous coronary interventions in diabetic patients: is complete revascularization important?

  2004cited by this paper
• Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina.

  2004cited by this paper
• Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.

  2004cited by this paper
• The effect of completeness of revascularization on event-free survival at one year in the ARTS trial.

  2002cited by this paper

• Guideline for Chronic Coronary Syndrome - 2025.

  2025cites this paper
• Key Messages and Critical Approach of the 2024 Guidelines of the European Society of Cardiology on Chronic Coronary Syndromes.

  2025cites this paper
• Association between Ranolazine, Ischemic Preconditioning, and Cardioprotection in Patients Undergoing Scheduled Percutaneous Coronary Intervention

  2024cites this paper
• Predictors of outcomes after PCI with incomplete revascularization: Impact of CTO and LAD vessel

  2024cites this paper
• Modulation of mitochondrial permeability transition pores in reperfusion injury: Mechanisms and therapeutic approaches

  2024cites this paper
• Angiogenic Gene Therapy for Refractory Angina: Results of the EXACT Phase 2 Trial

  2024cites this paper
• EXACT Trial: Results of the Phase 1 Dose-Escalation Study

  2023cites this paper
• Cardioprotective and Antianginal Efficacy of Nicorandil: A Comprehensive Review

  2023cites this paper
• Anti-ischemic and pleiotropic effects of ranolazine in chronic coronary syndromes.

  2023cites this paper
• Structured learning in time‐dependent Cox models

  2023cites this paper
• Effects of ranolazine on various outcomes in patients with stable angina: an updated meta-analysis.

  2022cites this paper
• Role of ranolazine in heart failure: From cellular to clinic perspective.

  2022cites this paper
• Angina in 2022: Current Perspectives

  2022cites this paper
• Efficacy of INtensive Treatment vs. Standard Treatment of COmpound DanshEn Dripping Pills in Refractory Angina Patients With Incomplete Revascularization (INCODER Study): Study Protocol for a Multicenter, Double-Blind, Randomized Controlled, Superiority Trial

  2021cites this paper
• Post-percutaneous coronary intervention angina: From physiopathological mechanisms to individualized treatment

  2021cites this paper
• Neurological complications of cardiovascular drugs.

  2021cites this paper
• HSOA Journal of Emergency Medicine Trauma and Surgical Care Perspective

  2021cites this paper
• Effectiveness and Tolerability of Trimetazidine 80 Mg Once Daily in Patients with Stable Angina Uncontrolled with Bisoprolol-Based Therapy: The Modus Vivendi Observational Study

  2021cites this paper
• State of the art approach to managing angina and ischemia: tailoring treatment to the evidence.

  2021cites this paper
• A pathophysiological compass to personalize antianginal drug treatment

  2021cites this paper
• Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment (The EXACT Trial): Rationale, Design, and Clinical Considerations.

  2021cites this paper
• What Is the Role of Assessing Ischemia to Optimize Therapy and Outcomes for Patients with Stable Angina and Non-obstructed Coronary Arteries?

  2021cites this paper
• Angina: contemporary diagnosis and management

  2020cites this paper
• Herztherapeutika

  2020cites this paper
• 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC)

  2020cites this paper
• ACPTI study: Being positive in a negative situation is not naivety – Trimetazidine still has role in symptomatic CAD patients

  2020cites this paper
• Management of refractory angina: an update.

  2020cites this paper
• The Role of Nicorandil in the Management of Chronic Coronary Syndromes in the Gulf Region

  2020cites this paper
• Trimetazidine and Bisoprolol to Treat Angina in Symptomatic Patients: Post Hoc Analysis From the CHOICE-2 Study

  2020cites this paper
• What we know and what we think we know: Perception of chest pain early after percutaneous coronary interventions.

  2020cites this paper
• Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial.

  2020cites this paper
• Non-pharmacological Treatment of Refractory Angina and Microvascular Angina

  2020cites this paper
• The Role of Ranolazine for the Treatment of Residual Angina beyond the Percutaneous Coronary Revascularization

  2020cites this paper
• Treatment of stable ischaemic heart disease: the old and the new

  2020cites this paper
• The New ESC Guidelines for the Diagnosis and Management of Chronic Coronary Syndromes: the Good and the Not So Good.

  2020cites this paper
• Role of endothelial dysfunction in determining angina after percutaneous intervention: Learning from pathophysiology to optimize treatment.

  2020cites this paper
• Chronic Stable Angina

  2020cites this paper
• Ranolazine: impact on quality of life in patients with stable angina pectoris, results from an observational study in Austria – the ARETHA AT study

  2019cites this paper
• A randomized, double‐blind, placebo‐controlled trial to assess the efficAcy and safety of Trimetazidine in patients with angina pectoris having been treated by percutaneous coronary intervention (ATPCI study): Rationale, design, and baseline characteristics

  2019cites this paper
• Relationship Between Optimism and Outcomes in Patients With Chronic Angina Pectoris.

  2019cites this paper
• Assessing Prognosis of Acute Coronary Syndrome in Recent Clinical Trials: A Systematic Review

  2019cites this paper
• The Impact of Cell Therapy on Cardiovascular Outcomes in Patients With Refractory Angina.

  2019cites this paper
• 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes.

  2019cites this paper
• Trimetazidine and Other Metabolic Modifiers.

  2018cites this paper
• 27 – Refractory Angina

  2018cites this paper
• Coronary Artery Disease in Patients ≥80 Years of Age.

  2018cites this paper
• Ranolazine: A true pluripotent cardiovascular drug or jack of all trades, master of none?

  2018cites this paper
• The Role of Ranolazine in Stable Coronary Angina and in Some Cardiac Arrhythmias

  2018cites this paper
• Measures of vascular dysfunction, monocyte subsets and circulating microparticles in patients with diffuse coronary artery disease

  2018influential citation
• Ranolazine: Multifaceted Role beyond Coronary Artery Disease, a Recent Perspective

  2018influential citation
• Cardiovascular drugs attenuated myocardial resistance against ischaemia-induced and reperfusion-induced injury in a rat model of repetitive occlusion

  2018cites this paper
• Linking cell function with perfusion: insights from the transcatheter delivery of bone marrow-derived CD133+ cells in ischemic refractory cardiomyopathy trial (RECARDIO)

  2018cites this paper
• Autologous CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trials

  2018cites this paper
• Enfermedad coronaria en pacientes de edad ≥ 80 años

  2018cites this paper
• Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators: The RAID Trial.

  2018cites this paper
• Angina and Its Management

  2017cites this paper
• ANMCO/GICR-IACPR/SICI-GISE Consensus Document: the clinical management of chronic ischaemic cardiomyopathy

  2017cites this paper
• Traditional and Alternative Therapies for Refractory Angina.

  2017cites this paper
• Ranolazine After Incomplete Percutaneous Coronary Revascularization in Patients With Versus Without Diabetes Mellitus: RIVER-PCI Trial.

  2017cites this paper
• Ranolazine in Diabetics With Stable Ischemic Heart Disease: Greatest Efficacy Related to Greatest Metabolic Stress.

  2017cites this paper
• Role of Ranolazine in cardiovascular disease and diabetes: Exploring beyond angina.

  2017cites this paper
• Improvement of Subjective Well-Being by Ranolazine in Patients with Chronic Angina and Known Myocardial Ischemia (IMWELL Study)

  2017cites this paper
• Ranolazine for stable angina pectoris.

  2017cites this paper
• Management of Persistent Angina After Myocardial Infarction Treated With Percutaneous Coronary Intervention: Insights From the TRANSLATE‐ACS Study

  2017cites this paper
• Medical treatment in multivessels coronary disease.

  2017cites this paper
• The coronary sinus reducer: clinical evidence and technical aspects

  2017cites this paper
• Reperfusion Damage　- A Story of Success, Failure, and Hope.

  2017cites this paper
• Advancements in pharmacotherapy for angina

  2017cites this paper
• Trimetazidine, Ranolazine, Ivabradine Antagonize Stable Coronary Artery Disease Otherwise from Conventional Anti-Ischemic Drugs

  2017cites this paper
• Pharmacological approaches of refractory angina.

  2016cites this paper
• Medical treatment of stable angina: A tailored therapeutic approach.

  2016cites this paper
• Post PCI Angina

  2016cites this paper
• Selección de temas de actualidad en cardiología intervencionista 2015

  2016cites this paper
• A Novel Intra-aortic Device Designed for Coronary Blood Flow Amplification in Unrevascularizable Patients

  2016cites this paper
• Can We Improve Myocardial Protection during Ischaemic Injury?

  2016cites this paper
• The year in cardiology 2015: coronary intervention.

  2016cites this paper
• Chronic Stable Angina.

  2016cites this paper
• Experimental and early investigational drugs for angina pectoris

  2016cites this paper
• Dedicated Bifurcation Stent for the Treatment of Bifurcation Lesions Involving Large Side Branches: Outcomes From the Tryton Confirmatory Study.

  2016cites this paper
• CLINICAL PRACTICE. Chronic Stable Angina.

  2016cites this paper
• Management standards for stable coronary artery disease in India

  2016cites this paper
• Overview of Management of Myocardial Ischemia: a Mechanistic-Based Approach

  2016cites this paper
• Ranolazine and Ivabradine: two different modalities to act against ischemic heart disease

  2016cites this paper
• The RENEW Trial: Efficacy and Safety of Intramyocardial Autologous CD34(+) Cell Administration in Patients With Refractory Angina.

  2016cites this paper
• Dedicated Bifurcation Stent for the Treatment of Bifurcation Lesions InvolvingLarge Side Branches

  2016cites this paper
• Ranolazine: A Contemporary Review

  2016influential citation
• Management of stable angina: A commentary on the European Society of Cardiology guidelines

  2016cites this paper
• Coronary artery disease: a dam in the river for ranolazine

  2016cites this paper
• Nationale Versorgungsleitlinie (NVL) Chronische KHK

  2016cites this paper
• [Triple antianginal combinations in the treatment of elderly and senile patients with stable angina].

  2016cites this paper
• Nationale Versorgungsleitlinie (NVL) Chronische KHK

  2016cites this paper
• Coronary Atherosclerosis: Pathophysiologic Basis for Diagnosis and Management.

  2016cites this paper
• Interventional Cardiology 2015: A Selection of Topical Issues.

  2016cites this paper
• The year in cardiology 2015: acute coronary syndromes.

  2016cites this paper
• Safety and efficacy of a device to narrow the coronary sinus for the treatment of refractory angina: A single-centre real-world experience

  2016cites this paper
• Ranolazine following percutaneous coronary intervention: For whom? For what?

  2016influential citation
• Management of Stable Angina – Current Guidelines: A Critical Appraisal

  2016cites this paper
• Alpha-crystallin: an ATP-independent complete molecular chaperone toward sorbitol dehydrogenase

  2005cites this paper
• ПРОГРАМА «СМАРТ ЕКГ – РАНОЛАЗИН»-ВЛАСНИЙ ДОСВІД

  year unknowncites this paper
• Therapeutic Possibilities in Patients with Refractory Angina Pectoris : Spinal Cord Stimulation

  year unknowncites this paper